peter kolchinsky age

Mariagrace previously worked as an Executive Assistant at MPM Capital. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. Soumya completed his postdoc at Brigham and Womens Hospital and held an Assistant Professor of Neuroscience role at Harvard Medical School Neurology Department where he contributed to the Harvard Neurodiscovery Centers (HNDC) academic drug discovery initiative as a modeler and drug hunter. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). His responsibilities include managing the portfolios public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . Joes primary responsibility at RA is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Gunes Bozkurt is an Analyst on the Venture Team at RA Capital Management. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. Prior to RAVen, he was a member of the founding team and Chief Operating Officer at Catamaran Bio, a CAR-NK cell therapy company. David Migl is an Analyst on the Investment Team at RA Capital Management. Laura Stoppel is a Principal on the Investment Team at RA Capital Management. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. He is also the co-founder of multiple biotechnology companies including HiFiBiO and Design Pharmaceuticals. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. He served on the Scientific Advisory Boards of multiple companies including DNA Script, Danaher Life Sciences, and CircBio. Eric is the Chief Compliance Officer at RA Capital Management. Christina is a Senior Science Writer at RA Capital Management. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Bethany is a Senior Finance Associate at RA Capital Management. Peyman holds a dual B.S. His graduate research investigated innate immune responses after intracerebral hemorrhage. Senior Research Assistant, Venture Analytics. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. Maxs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. RA Capital and CEO of Arcuate Therapeutics. Joel brings 40 years of BioPharma drug discovery and development experience to that role. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. Kriti holds a B.S. Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Before entering the life science space, Kat held various accounting roles in the retail industry and started her career at Ernst & Young. James primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. Priscilla previously held a Senior Scientist role at Sanofi. His doctoral research focused on breast cancer metastasis. He previously worked as a corporate attorney at Foley Hoag LLP and Cooley LLP. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. Cony D'Cruz is a Venture Partner at RA Ventures. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Camerons primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. Ed began his career working with neurologically active compounds at Allergan, CoCensys, and Serono. Americas +1 212 318 2000. Brian previously worked at the Kraft Group LLC, where he led their system admin, network, and desktop engineering groups. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Timothy Noyes is an Advisor for RA Capital Management. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. He oversees the firm's financial functions, including middle office operations, accounting, valuation, tax and financial reporting. In his Venture role, Mario is focusing on early-stage investment and company creation. Cristina Ghenoiu is a Principal on the Venture Team at RA Capital Management. and Novus Biologicals. Prior to Vor, Sadik served as Executive Director at Kite Pharma and led the development of manufacturing processes for autologous CAR-T and TCR-based cell therapies. Zach works on both public and private investments and serves as a Board Director for Adagio Medical, Exo Imaging, LENZ Therapeutics, Nkarta Therapeutics, and Sydnexis. Tess Cameron is a Principal on the Investment Team at RA Capital Management. In addition, he designs graphics for all internal and external materials. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. Brackett has a BS in Biology with a minor in Spanish from Davidson College. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and -thallasemia. Shannon is a Receptionist and Facilities Administrator at RA Capital Management. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . He previously served as the CFO of Research Alliance Corp I before its merger with Point Biopharma and served on the boards of Research Alliance Corp I and Research Alliance Corp II. Brigid's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. Rez brings to RA over 20 years of experience working in the life-science industry. Ben has also mapped competitive landscapes with a focus on cardiovascular diseases and regenerative medicine as a member of the Cardio-Renal Team within the TechAtlas division of RA Capital. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Prior to RA, Gunes served as a scientist within the PCMM Program at Boston Childrens Hospital and her research focused on biophysical characterization of different amyloid fibrils. Brackett Hardy is a Junior Associate with the TechAtlas division of RA Capital Management. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Rajeev Shah is a Managing Partner at RA Capital Management. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. Vanderpump Rules' Peter Madrigal's Age. Lorena's primary responsibility is to oversee all accounting related activities for the firm. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Anthony Arceci is a Senior Associate with the TechAtlas division of RA Capital Management. Chris Caliri is the Chief Information Officer at RA Capital Management. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the companys CSO. Ally coached Women's Lacrosse at Muhlenberg College in PA. in Business Administration in Management Information Systems from Northeastern University. She has spent the last five years as a Senior Finance Associate at Great Hill Partners. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. His research investigated chromatin structure and transcription factor binding. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. Michael Sherman is a Venture Partner at RA Ventures. Timothy is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Dan Marks is a Principal on the Venture Team at RA Capital Management. Gerald is Vice President of Scientific Operations at RA Ventures (RAVen). Ding Sun is a Senior Software Engineer at RA Capital Management. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. Prior to Point32Health, Michael served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). As the first and founding member of Kymeras scientific team, Jesse was responsible for building the companys industry-leading targeted protein degradation platform and pipeline, and he helped secure the companys Series A and B financings as well as a partnership with Vertex. Danielle received her PhD in Neuroscience from the Massachusetts Institute of Technology. She holds a BS in Finance from Elon University and an MBA from Babson College. Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. Her contributions involve engagement with teams across RA Capital, including the processing of CDA's. Kates primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Kyle Teamey joins RA Capital as a Managing Partner, Planetary Health. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Prior to Longitude Capital, Cristina held an Associate Analyst role in Biotechnology Equity Research at Cowen. Alex Martinez-Forte is an Analyst, Strategic Finance at RA Capital Management. Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. Tom is a Senior Operations Analyst at RA Capital Management. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. Peter Kolchinsky (PhD '01) is a co-founder and General Partner of RA Capital Management, which has been investing in healthcare companies since 2002.He is a member of the National Academies Board on Global Science and Technology, authored an e-book titled The Entrepreneur's Guide to a Biotech Startup, and serves as an advisor to startup companies and non-profits. Her primary responsibilities are to assist with all finance operations related to the Firm. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Our website uses cookies to distinguish you from other users of our website. Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Prior to RA, Rob spent 21 years at the Broad Institute of MIT and Harvard, most recently as the Senior Director of Technology Development and a Principal Investigator. Ally brings to RAVen nearly a decade of administrative experience. Tess works on both public and private investments and serves on several company boards. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Previously, Rebecca worked as a Senior Associate within RAs TechAtlas division. Chris primary responsibility at RA Capital is to oversee the firms information technology program, including operations, development, and security. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. Garrett Heffner is an EIR at RA Ventures, focusing on genetic medicines. Drews primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. From time to time we may post specific open positions, but more often we will create positions for the right people. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Prior to RA Capital, Tyler worked as a freelance graphic designer. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. After leaving Schrodinger in 2018, Soumya founded 3-Dimensional Consulting, a boutique Physics Based and Machine-Learning focused computational chemistry consulting firm that provides scientific support for early-stage drug discovery and company formation within various Boston-based venture firms including: Atlas Venture, 3rd Rock, MPM Capital, and RA Capital. Cristinas primary responsibility is to identifying compelling opportunities to help facilitate new company creation and early stage investing. Michael held leadership positions at Citigroup Hedge Fund Services in both Fund Accounting and Product Management before joining Centerbridge. Prior to Merck, he was a Partner with the Partners Innovation Fund, the corporate venture arm of Mass General Brigham hospital (formerly Partners HealthCare), where he invested in Seed/Series A therapeutics-focused companies. Prior to RA Capital, Tom worked as an Associate at Flagship Pioneering. Emily Greenis a Visual Identity Designer at RA Capital Management. Prior to Bernstein, Joey held a Consultant role at FactSet. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University. April 28, 2023 Updated: April 28, 2023 4:29 p.m. 8. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital. Fuad Naser is a Senior Associate with the TechAtlas division of RA Capital Management. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. Peymans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. In this role, Gerald is responsible for evaluating new technology and novel biology to originate and support the generation of new companies in collaboration with RAVens Venture Partners and EIRs. Walter's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Most recently, David served as Director of Operations at Corbin Capital Partners, LP. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Barrie's classic tale and has a somewhat dark look and feel. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College. Gunes conducts due diligence on biotechnology companies at RA Capital. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors. Peter founded and serves as a Director ofNo Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a JD from Northeastern University School of Law and a BS in Biology from Tufts University. Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. Jeff Breay is a Head Trader at RA Capital Management. Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. (L-R) Robert Morgan, Jamie Anderson and Mark Blutman, collaborators on forthcoming 'Arigato Tokyo' Courtesy/Getty. Her graduate research investigated inhibitors of influenza virus and characterizing hydrophobic polycationic antimicrobial surfaces. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. Peter also leads the firms engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. Raj holds a BA from Cornell University, where he majored in Chemistry. Rebecca Silberman is an Analyst on the Venture Team at RA Capital Management. Previously, Emily spent over seven years at Celgene Corporation in positions of increasing responsibility in business development, marketing, operations, and as Principal to the Chairman and CEO. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Dans primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Lucas Guevara is a Compliance Counsel at RA Capital Management. TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University. They will discuss the origins and history . Neil was a founder or founding team member of six companies incubated within RA Ventures, including Lusaris Therapeutics, Eliem Therapeutics ($ELYM), Aerovate Therapeutics ($AVTE), Imbria Pharmaceuticals, and Athenen Therapeutics (acquired by Eliem). He worked previously as a Patient Coordinator at Massachusetts General Hospital. He is a respected biotech leader with over twenty years of biopharma experience across global organizations. Davids primary responsibility is to oversee the development and implementation of treasury functions for the firm. Brian has a B.S. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Asia Pacific +65 6212 1000. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Phi previously worked as an Executive Assistant at Relay Therapeutics. Jaimie Kirkpatrick is a Research Assistant at RA Capital Management. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Emily started her career in strategy consulting at Frankel Group. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments. Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA. Jacqueline is an Associate, Strategic Finance at RA Capital Management. Lorena Chen is a Fund Controller at RA Capital Management. Michael Varnum is a Research Assistant at RA Capital Management. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. Craig is admitted to practice law in the Commonwealth of Massachusetts. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. Kathryn previously held roles as Executive Assistant and Office Manager at Kojin Tx. Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Michael is the Chief Financial Officer at RA Capital Management. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. do insurance companies look at street cameras, brian waldron broadcaster,
How To Shift A Lenco Transmission, What Does It Mean When A Guy Says Goodnight You, Judge Rahill Ocean County Nj, Does Extraordinary Bites Bread Need To Be Refrigerated, Brave Home Ez Trolley 6 Drawer, Articles P